Any cancer diagnosis is scary, but for men diagnosed with prostate cancer and women diagnosed with ovarian cancer, uncertainty regarding diagnosis, side effects of treatment and support groups that are available can make their battle with cancer even scarier. Penn State Milton S. Hershey Medical Center's Joshua Kesterson, a gynecologic oncology specialist, and Joseph Drabick, specialist in hematology and oncology, offered some answers to important questions.
A motor regulatory protein can block human ovarian tumor growth, leading to eventual cancer cell death and possible new therapies to treat the disease, according to Penn State College of Medicine researchers.
Renee Donahue, a fourth-year cell and molecular biology doctoral student at the Penn State College of Medicine, has been accepted to the National Institute of Health's (NIH) annual National Graduate Student Research Festival to be held on Nov. 12 and 13.
This year's festival introduces 200 advanced graduate students to the NIH Intramural Research Program, with the aim of recruiting them for postdoctoral training at NIH. The IRP is the world's largest institution focused exclusively on biomedical research. The festival also allows the students to present their research and tour the NIH's extensive research and clinical facilities. Donahue, a student in the laboratories of Pat McLaughlin and Ian Zagon, will present her research on ovarian cancer.
In recent years, several new innovations have been employed in the treatment for women with gynecologic cancer in an effort to preserve fertility. These innovations consist of conservative ovarian staging, embryo/oocyte cryopreservation, hormonal treatment of endometrial cancer, and fertility-sparing radical hysterectomy for women with cervical cancer, according to this week's edition of The Medical Minute, a service of the Penn State Milton S. Hershey Medical Center.